Alvotech Welcomes Stelara Biosimilar Into Phase III Development
Joins Alvotech’s Biosimilar Humira Candidate
Executive Summary
Alvotech has announced two studies running in parallel for the firm’s AVT04 ustekinumab biosimilar referencing Janssen’s $7.7bn Stelara treatment for autoimmune diseases, including a Phase III comparative study.